Dyne Therapeutics, Inc. (DYN) · Sep 29, 2026 · Other events

Dyne Therapeutics clinical data show durable DM1 gains, but pooled doses blur proof

1-year efficacy update — QMT +9.9%, 5xSTS -11.5%, MDHI -25.2% at 12 months

Dyne Therapeutics’ clinical data update shows sustained one-year strength and function gains in DM1, though the analysis relies on mixed-dose patients.

Dyne is advancing z-basivarsen from a positive Phase 1/2 DM1 signal toward registrational testing: the company completed enrollment in the ACHIEVE registrational expansion cohort and has begun the confirmatory HARMONIA Phase 3 program.

The one-year signal remains directionally strong across meaningful measures. In the pooled ACHIEVE group, quantitative muscle strength improved 9.9% from baseline at 12 months, the 5-times-sit-to-stand time improved 11.5%, and patient-reported disease burden on MDHI improved 25.2% (12-month efficacy slides). The consistency across strength, mobility and patient-reported outcomes makes this more useful than a single biomarker or myotonia readout.

The comparison against natural history strengthens the case that this may be treatment effect, not just noise. At one year, the pooled group improved while matched END-DM1 participants generally worsened on total strength, hand grip and walking time; the filing also says MDHI improvement exceeded a minimal clinically important difference. 〔0〕 〔1〕

Measure12-month changeComparison / context
QMT total strength+9.9% from baselinePooled dose group, N=25
Hand-grip strength+11.2% from baselinePooled dose group, N=25
5-times sit-to-stand-11.5% timePooled dose group, N=26
10-meter walk/run-6.4% timePooled dose group, N=26
MDHI total score-25.2%Pooled dose group, N=25
Treatment-emergent adverse events100% had at least oneOverall safety population, N=56

The main limitation is that the headline efficacy analysis is not a clean registrational-dose result. The pooled group combines 3.4, 5.4 and 6.8 mg/kg cohorts, and only 8 of 26 participants received the 6.8 mg/kg registrational dose for the entire 12 months. 〔2〕 That makes the result supportive, but it cannot establish how the selected dose will perform in the larger registrational cohort.

Safety remains workable, but not uneventful. No serious treatment-related adverse events or deaths were reported, although infusion reactions were common and liver-enzyme elevations occurred in a minority of participants. 〔3〕 The safety database is also still small for a therapy intended for broader use, despite roughly 1,300 doses administered and more than 143 patient-years of follow-up. 〔4〕

Bottom line: This update advances Dyne’s DM1 story from early biological activity toward a credible functional-benefit profile, with natural-history comparisons adding support. It is encouraging rather than definitive because the strongest one-year data come from a small, mixed-dose pooled group; the larger registrational readout remains the real test, currently planned for the first quarter of 2027.

What to watch next

ACHIEVE topline data, Q1 2027

Original filing on SEC EDGAR

More Dyne Therapeutics, Inc. news

Dyne Therapeutics clinical data show durable DM1 gains, but pooled doses blur proof | DYN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.